Latest news
Myeloma Patients May Not Need Treatment Forever
The ENDURANCE trial found no overall survival benefit from indefinite lenalidomide maintenance compared with stopping after two years in standard-risk, newly diagnosed multiple myeloma patients who did not undergo transplant. This is a de-escalation story with real cost and quality-of-life consequences.
Pregnancy Vaccines Become a Trust Test as Medical Societies Step In
Precision cardiology is becoming the new oncology. Policy and reimbursement must catch up
CAR-T Starts Moving From Factory Medicine to In-Patient Engineering
AML’s Frontline Future Starts With Finding the Mutation Fast
Cellular Reprogramming Enters Neuro-Ophthalmology
Screwworm Turns Pet Treatment Into a One Health Preparedness Issue
Chronic pain may be a cardiovascular warning sign, not just a symptom
IPM Brief – Issue 3 | The Future Arrived Early. The System Didn’t.
Cancer Is Chaos. Patients Should Not Have to Become Their Own Operating System
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.